Home › Funds › SymBiosis Capital Partners, LLC › EVMN

SymBiosis Capital Partners, LLC position in EVMN

EVOMMUNE INC · Health Care

SymBiosis Capital Partners, LLC reported holding 1,280,778 shares of EVMN (EVOMMUNE INC) in its Q1 2026 13F filing — a position valued at US$29.4M, representing 55.80% of its reported portfolio and ranking #1 among its reported holdings. SymBiosis Capital Partners, LLC has disclosed EVMN holdings in 2 of the last 2 reported quarters, going back to Q4 2025.

Latest position (Q1 2026)1.28M sh
Reported value held$29.45M
Portfolio Weight55.80%
First reportedQ4 2025
Last changeHold
Updated2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

How SymBiosis Capital Partners, LLC's EVMN position evolved

SymBiosis Capital Partners, LLC first disclosed a stake in EVMN in Q4 2025 at 1,280,778 shares (US$21.9M). The position peaked in Q1 2026 at 1,280,778 shares, worth US$29.4M. Across 2 filings, SymBiosis Capital Partners, LLC held the position steady without any share-count change. The most recent filing (Q1 2026) shows 1,280,778 shares valued at US$29.4M.

Quarter by quarter

QuarterSharesValueChange
Q4 2025 1.28M $21.93M New
Q1 2026 1.28M $29.45M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About EVMN and 13F data

EVMN (EVOMMUNE INC) is a Health Care company. 116 other funds we track also report a position in EVMN — the largest reported positions include EQT Fund Management S.a r.l. (US$70.3M), RA CAPITAL MANAGEMENT, L.P. (US$46.4M), Pivotal bioVenture Partners Investment Advisor LLC (US$25.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding EVMN

All EVMN fund holders →

FAQ

How long has SymBiosis Capital Partners, LLC held EVMN?

SymBiosis Capital Partners, LLC has disclosed EVMN holdings in 2 of the last 2 reported quarters, going back to Q4 2025.

What is SymBiosis Capital Partners, LLC's current position in EVMN?

As of Q1 2026, SymBiosis Capital Partners, LLC holds 1.28M shares of EVMN (EVOMMUNE INC), valued at $29.45M, representing 55.80% of its reported portfolio and ranking #1.

Has SymBiosis Capital Partners, LLC been buying or selling EVMN?

In the latest 13F filing (Q1 2026), SymBiosis Capital Partners, LLC held unchanged its position in EVMN. The position peaked in Q1 2026 at 1.28M shares.

Which other funds hold EVMN?

Other major institutional holders of EVMN include EQT Fund Management S.a r.l., RA CAPITAL MANAGEMENT, L.P., Pivotal bioVenture Partners Investment Advisor LLC, among 116 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.